Fulgent Genetics (MEX:FLGT) Cyclically Adjusted Revenue per Share: MXN378.51 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:FLGT Fulgent Genetics Inc MEX:FLGT
56 GF Score
Price MXN372.00
GF Value MXN450.98
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Cyclically Adjusted Revenue per Share?

Fulgent Genetics MEX:FLGT 56 Cyclically Adjusted Revenue per Share is MXN378.51 as of Mar. 2026. GuruFocus rates MEX:FLGT with a GF Score™ of 56/100 and a GF Value™ of MXN450.98 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Fulgent Genetics's adjusted revenue per share for the three months ended in Mar. 2026 was MXN41.540. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN378.51 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fulgent Genetics's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-24), Fulgent Genetics's current stock price is MXN372.00. Fulgent Genetics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN378.51. Fulgent Genetics's Cyclically Adjusted PS Ratio of today is 0.98.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Fulgent Genetics was 2.59. The lowest was 1.16. And the median was 1.81.


Fulgent Genetics  (MEX:FLGT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Fulgent Genetics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=372.00/378.51
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Fulgent Genetics was 2.59. The lowest was 1.16. And the median was 1.81.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Fulgent Genetics Cyclically Adjusted Revenue per Share Related Terms


Fulgent Genetics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Cyclically Adjusted Revenue per Share Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 211.23

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 218.50 187.08 176.01 211.23 378.51

MEX:FLGT vs MYGN, CSTL, BDSX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Cyclically Adjusted PS Ratio falls into.


MEX:FLGT
56GF Score
Fulgent Genetics Inc MEX:FLGT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fulgent Genetics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=41.54/330.2130*330.2130
=41.540

Current CPI (Mar. 2026) = 330.2130.

Fulgent Genetics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.209 241.018 5.767
201609 7.542 241.428 10.316
201612 6.907 241.432 9.447
201703 5.496 243.801 7.444
201706 4.736 244.955 6.384
201709 4.603 246.819 6.158
201712 4.719 246.524 6.321
201803 4.732 249.554 6.261
201806 5.921 251.989 7.759
201809 5.841 252.439 7.641
201812 6.148 251.233 8.081
201903 5.715 254.202 7.424
201906 8.507 256.143 10.967
201909 10.499 256.759 13.503
201912 8.004 256.974 10.285
202003 8.430 258.115 10.785
202006 17.387 257.797 22.271
202009 95.459 260.280 121.107
202012 218.789 260.474 277.367
202103 238.774 264.877 297.671
202106 99.185 271.696 120.547
202109 150.318 274.310 180.952
202112 165.548 278.802 196.075
202203 204.125 287.504 234.448
202206 80.849 296.311 90.099
202209 68.852 296.808 76.601
202212 43.228 296.797 48.095
202303 40.380 301.836 44.176
202306 39.019 305.109 42.229
202309 49.151 307.789 52.732
202312 40.202 306.746 43.278
202403 35.950 312.332 38.008
202406 43.233 314.175 45.440
202409 46.444 315.301 48.641
202412 51.851 315.605 54.251
202503 48.745 319.799 50.332
202506 50.428 322.561 51.624
202509 50.154 324.800 50.990
202512 48.429 324.054 49.349
202603 41.540 330.213 41.540

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN378.51 mean?
Fulgent Genetics (MEX:FLGT) has a Cyclically Adjusted Revenue per Share of MXN378.51 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Cyclically Adjusted Revenue per Share too high?
Fulgent Genetics' current Cyclically Adjusted Revenue per Share is MXN378.51. Overall, Fulgent Genetics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Cyclically Adjusted Revenue per Share compare to MYGN and CSTL?
Fulgent Genetics' Cyclically Adjusted Revenue per Share of MXN378.51 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Cyclically Adjusted Revenue per Share is MXN378.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (MEX:FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN450.98, compared to a current price of MXN372.00 — trading 17.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN378.51. Fulgent Genetics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Fulgent Genetics (MEX:FLGT), the current Cyclically Adjusted Revenue per Share is MXN378.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (MEX:FLGT) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of MXN372.00 is trading 17.5% below its estimated GF Value™ of MXN450.98. GuruFocus considers Fulgent Genetics to be Modestly Undervalued.

Key valuation signals for MEX:FLGT:

  • Cyclically Adjusted Revenue per Share: MXN378.51
  • GF Value™: MXN450.98 vs. price of MXN372.00 (17.5% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the MEX:FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fulgent Genetics Business Description

Other Exchanges FLGT:USA
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
56GF Score

Get the complete analysis for MEX:FLGT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN372.00
Price
MXN450.98
GF Value